Business ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Obesity Treatments FDA Approval Weight Loss Drugs Schizophrenia Treatments Obesity Drugs Combination Therapy CagriSema Gilead Sciences Phase I Trial Phase II Trial Weight Loss Treatments Market Analysis Liver Therapies Polilaminina Obexelimab Weight Loss Medications Regulatory Approval Psychoactive Drugs Market Potential RNA-based Therapies Asundexian Efficacy Studies Zaltenibart Atezolizumab Anti-inflammatory Drugs Hemophilia Treatments Biomarkers Prostate Cancer Therapeutics Alzheimer's Disease Market Impact Hair Loss Treatments Acasunlimab Cancer Treatments Psilocybin Therapy Eli Lilly and Company AI in Drug Discovery Bayer Novo Nordisk Synthetic Psilocybin Eli Lilly

Lilly’s Taltz Plus Zepbound Outperforms Taltz Alone in Phase 3b Psoriasis-Obesity Trial

The 36-week study in a high‑BMI psoriasis population met its primary goal, with tolerability in line with known effects.

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

Genmab Halts Acasunlimab to Focus on Late-Stage Cancer Portfolio

Kymera Jumps on KT-621 Phase 1b Win, Advancing Oral STAT6 Degrader Into Phase 2b

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory

Eli Lilly Halts Diabetes Arm of Bimagrumab Obesity Trial Weeks After Launch

AbbVie Agrees to Buy Gilgamesh’s Bretisilocin for Up to $1.2 Billion